Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 4, 2009 - Issue 2
Submit an article Journal homepage
362
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Explaining hormone-deprivation therapy failure in prostate cancer patients

Jun Luo Department of Urology, 600 N. Wolfe St, Johns Hopkins University, Baltimore, MD 21287, USA. [email protected]
Pages 103-105 | Published online: 10 Jan 2014

References

  • Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J. Urol.168(1), 9–12 (2002).
  • Maroni PD, Crawford ED. The benefits of early androgen blockade. Best Pract. Res. Clin. Endocrinol. Metab.22(2), 317–329 (2008).
  • Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol. Endocrinol.21(12), 2855–2863 (2007).
  • Fleming MT, Morris MJ, Heller G, Scher HI. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat. Clin. Pract. Oncol.3(12), 658–667 (2006).
  • Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol.8(4), 440–448 (2008).
  • Small EJ, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. J. Urol.176(6 Pt 2), S66–S71 (2006).
  • Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr. Relat. Cancer6(4), 503–519 (1999).
  • Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med.10(1), 33–39 (2004).
  • Linja MJ, Visakorpi T. Alterations of androgen receptor in prostate cancer. J. Steroid Biochem. Mol. Biol.92(4), 255–264 (2004).
  • Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer120(4), 719–733 (2007).
  • Kaarbo M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays29(12), 1227–1238 (2007).
  • Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract. Res. Clin. Endocrinol. Metab.22(2), 243–258 (2008).
  • Hu R, Dunn TA, Wei S et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res.69(1), 16–22 (2009).
  • Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res.68(13), 5469–5477 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.